Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Program Overview

The goal of this activity is to provide clinicians with the clinical tools necessary to identify and manage treatment-refractory and drug-resistant CMV in patients after solid organ transplantation (SOT). A panel of infectious diseases experts review current CMV treatment guidelines, discuss antiviral resistance testing, and provide insights for management with a new antiviral therapeutic option. An experienced patient with CMV provides important practical take-aways for clinicians to use with their own SOT patients.

0.75 CE Credit(s)

Expires: April 12, 2024

Target Audience

Transplantation, infectious diseases, nephrology, internal medicine, and pharmacy clinicians who manage patients with refractory or resistant cytomegalovirus (CMV) after solid organ transplantation.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Employ current CMV treatment guidelines for the use of antiviral therapies and management of their adverse effects
Identify treatment-refractory and drug-resistant CMV by correctly interpreting antiviral resistance testing results
Select transplant patients who will benefit from the efficacy and reduced toxicity of new CMV therapy

Activity Faculty

Atul Humar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada

Raymund R. Razonable, MD, FIDSA, FAST

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota, United States